Leqembi® approved for the treatment of Alzheimer’s disease in China
Stockholm, Sweden, January 9, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name in China: “乐意保”, generic name: lecanemab-irmb) has been approved in China as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023. Eisai’s preparations for the Chinese launch in the of the third quarter 2024 are underway.Amyloid-beta (Aβ) is